Last reviewed · How we verify
Conventional adjuvant FOLFOX
FOLFOX is a chemotherapy regimen that combines fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce cell death in cancer cells.
FOLFOX is a chemotherapy regimen that combines fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce cell death in cancer cells. Used for Adjuvant treatment of stage III colon cancer, Adjuvant treatment of stage II colon cancer (high-risk features).
At a glance
| Generic name | Conventional adjuvant FOLFOX |
|---|---|
| Sponsor | Kyungpook National University Hospital |
| Drug class | Chemotherapy regimen (combination of antimetabolite and platinum agent) |
| Target | Thymidylate synthase (5-FU); DNA (oxaliplatin cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX works through multiple mechanisms: fluorouracil (5-FU) inhibits thymidylate synthase and is incorporated into DNA/RNA to disrupt synthesis; leucovorin enhances 5-FU activity by stabilizing its binding to thymidylate synthase; oxaliplatin forms DNA cross-links that prevent replication. This combination is particularly effective in colorectal cancer as an adjuvant (post-surgical) treatment to eliminate residual micrometastatic disease.
Approved indications
- Adjuvant treatment of stage III colon cancer
- Adjuvant treatment of stage II colon cancer (high-risk features)
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
- Fatigue
- Mucositis
Key clinical trials
- Early Commencement of Adjuvant Chemotherapy for Colon Cancer (PHASE3)
- Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer (PHASE2)
- Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer (PHASE3)
- SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases (PHASE2)
- Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (PHASE1)
- Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer (PHASE2)
- Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients (NA)
- Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional adjuvant FOLFOX CI brief — competitive landscape report
- Conventional adjuvant FOLFOX updates RSS · CI watch RSS
- Kyungpook National University Hospital portfolio CI